NCT04305834: Abemaciclib Monotherapy in Treating Older Patients With Hormone Receptor Positive Metastatic Breast Cancer

NCT04305834
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Suspended
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 70 Years and older (Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients who have not progressed on prior endocrine therapy or palbociclib or ribociclib or chemotherapy; Patients with symptomatic, unstable, untreated brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT04305834

Comments are closed.

Up ↑